NXTC vs. TLSA, ANL, VTGN, CLSD, THTX, ASRT, GNTA, PYRGF, IMAB, and PYXS
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Tiziana Life Sciences (TLSA), Adlai Nortye (ANL), Vistagen Therapeutics (VTGN), Clearside Biomedical (CLSD), Theratechnologies (THTX), Assertio (ASRT), Genenta Science (GNTA), PyroGenesis Canada (PYRGF), I-Mab (IMAB), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.
NextCure vs.
Tiziana Life Sciences (NASDAQ:TLSA) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
In the previous week, Tiziana Life Sciences had 5 more articles in the media than NextCure. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 0 mentions for NextCure. Tiziana Life Sciences' average media sentiment score of 0.40 beat NextCure's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.
42.7% of NextCure shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 13.3% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NextCure has a consensus price target of $4.00, indicating a potential upside of 453.33%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Tiziana Life Sciences.
Tiziana Life Sciences has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Tiziana Life Sciences' return on equity of 0.00% beat NextCure's return on equity.
Tiziana Life Sciences received 16 more outperform votes than NextCure when rated by MarketBeat users. However, 64.52% of users gave NextCure an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
Summary
Tiziana Life Sciences beats NextCure on 8 of the 13 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
This page (NASDAQ:NXTC) was last updated on 2/22/2025 by MarketBeat.com Staff
